PreScription DigitaL ThErapEutic for Patients with Insomnia (SLEEP-I): A Protocol for a Pragmatic Randomized Controlled Trial [article]

Rachel P Dreyer, Alyssa Berkowitz, Henry Klar Yaggi, Lynelle Schneeberg, Nilay D Shah, Lindsay Emanuel, Bhanu Prakash Kolla, Molly Moore Jeffery, Mark Deeg, Keondae R Ervin, Frances Thorndike, Joseph S. Ross
2022 medRxiv   pre-print
Cognitive behavioral therapy for insomnia (CBT-I) is effective at treating chronic insomnia, yet in-person CBT-I can often be challenging to access. Prior studies have used technology to bridge barriers but have been unable to extensively assess the impact of the digital therapeutic on real-world patient experience and multi-dimensional outcomes. Among patients with insomnia, our aim is to determine the impact of a Prescription Digital Therapeutic (PDT) (PEAR-003b, FDA-authorized as Somryst;
more » ... ein called PDT) that provides mobile-delivered CBT-I on patient-reported outcomes (PROs) and healthcare utilization. Methods and Analysis: We are conducting a pragmatically designed, prospective, multi-center randomized controlled trial that leverages Hugo, a unique patient-centered health data-aggregating platform for data collection and patient follow-up from Hugo Health. A total of 100 participants with insomnia from two health centers will be enrolled onto the Hugo Health platform, provided with a linked Fitbit (Inspire 2) to track activity, and then randomized 1:1 to receive (or not) the PDT for mobile-delivered CBT-I (Somryst). The primary outcome is a change in the insomnia severity index score (ISI) score from baseline to 9-weeks post-randomization. Secondary outcomes include healthcare utilization, health utility scores, and clinical outcomes; change in sleep outcomes as measured with sleep diaries; and a change in individual PROs including depressive symptoms, daytime sleepiness, health status, stress, and anxiety. For those allocated to the PDT, we will also assess engagement with the PDT. Ethics and Dissemination: The Institutional Review Boards at Yale University and the Mayo Clinic have approved the trial protocol. This trial will provide important data to patients, clinicians, and policymakers about the impact of the PDT device delivering CBT-I on PROs, clinical outcomes, and healthcare utilization. Findings will be disseminated to participants, presented at professional meetings, and published in peer-reviewed journals.
doi:10.1101/2022.02.26.22271430 fatcat:c5f7auzck5ctdcxehdxgjuyodq